PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
This article is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Review previously published in the Cochrane Database of Systematic Reviews. Original publication: Schmidt AF, Carter J-PL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas J. PCSK9 monoclonal antibod...
Saved in:
| Main Author: | article Editorial |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2023-12-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/412 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Does vitamin D supplementation benefit, harm, or have no effects on pregnant women or their babies?
by: article Editorial
Published: (2024-10-01) -
New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01) -
Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis
by: Leyu Xu, et al.
Published: (2025-06-01) -
PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01) -
Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01)